Department of Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Department of Pathology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Aging (Albany NY). 2021 Jun 4;13(11):15413-15432. doi: 10.18632/aging.203100.
Although disease susceptibility is known to differ between men and women, it is controversial whether the efficacy of immune checkpoint inhibitors for malignancies also differs between the sexes. We conducted a meta-analysis to explore the impact of sex on immune checkpoint inhibitor treatment outcomes. We searched PubMed, Embase and the Cochrane Library databases from inception to October 1, 2020 for randomized controlled trials of immune checkpoint inhibitors with hazard ratios (HRs) stratified by sex. We calculated the pooled HRs for men and women using the ln(HR), and assessed the heterogeneity between the two estimates through an interaction test. In total, 22,268 patients from 39 randomized controlled trials were included. Immune checkpoint inhibitors yielded better overall survival than conventional agents in both men (HR: 0.75, 95% confidence interval [CI]: 0.71-0.80) and women (HR: 0.77, 95% CI: 0.70-0.85). Progression-free survival benefits were also observed in both men (HR: 0.64, 95% CI: 0.58-0.70) and women (HR: 0.67, 95% CI: 0.58-0.77) treated with immune checkpoint inhibitors. No sex differences in the response to immune checkpoint inhibitors were found when overall survival and progression-free survival were used as the endpoints.
尽管已知男性和女性的疾病易感性存在差异，但免疫检查点抑制剂治疗恶性肿瘤的疗效是否也存在性别差异仍存在争议。我们进行了一项荟萃分析，以探讨性别对免疫检查点抑制剂治疗结果的影响。我们从建库到 2020 年 10 月 1 日在 PubMed、Embase 和 Cochrane 图书馆数据库中搜索了按性别分层的免疫检查点抑制剂的随机对照试验，检索了 hazard ratios（HRs）。我们使用 ln(HR) 计算了男性和女性的汇总 HR，并通过交互检验评估了这两个估计值之间的异质性。总共纳入了来自 39 项随机对照试验的 22268 名患者。与传统药物相比，免疫检查点抑制剂在男性（HR：0.75，95%置信区间[CI]：0.71-0.80）和女性（HR：0.77，95%CI：0.70-0.85）中均能带来更好的总生存获益。在男性（HR：0.64，95%CI：0.58-0.70）和女性（HR：0.67，95%CI：0.58-0.77）中，免疫检查点抑制剂也能带来无进展生存期获益。当将总生存期和无进展生存期作为终点时，并未发现免疫检查点抑制剂的反应存在性别差异。
